Tg Therapeutics (TGTX) Gains from Investment Securities (2013 - 2026)

Tg Therapeutics' Gains from Investment Securities history runs 14 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 22.98% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $5.8 million (up 29.53% YoY), while the FY2025 annual figure was $4.2 million, down 5.94% from the prior year.
• Gains from Investment Securities was $3.4 million for Q1 2026 at Tg Therapeutics, up from $845000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $9.2 million in Q1 2023 to a low of -$2.2 million in Q4 2022.
• Historically, Gains from Investment Securities has averaged $2.5 million across 5 years, with a median of $1.5 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities jumped 84014.8% in 2022, then sank 94.38% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at -$2.2 million in 2022, then surged by 33.2% to -$1.5 million in 2023, then soared by 133.94% to $500000.0 in 2024, then surged by 69.0% to $845000.0 in 2025, then soared by 306.98% to $3.4 million in 2026.
• The last three Gains from Investment Securities figures came in at $3.4 million (Q1 2026), $845000.0 (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.